BBNX
What one share of Beta Bionics holds
Surgical and Medical Instruments and Apparatus
We are a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease.
Beta Bionics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.69 |
|---|---|
| Profit | −$1.65 |
| Capex (buildings and equipment) | $0.13 |
| Free cash flow | −$1.39 |
| Cash and investments | $0.99 |
| Book value | $5.70 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $2.26 | −$8.31 | $0.08 | −$6.19 | — | −$38.30 |
| 2024 | $10.23 | −$8.60 | $0.53 | −$8.12 | — | −$36.80 |
| 2025 | $2.47 | −$1.81 | $0.13 | −$1.39 | — | $6.48 |